Rep. Marjorie Taylor Greene Critiques FDA’s Approval of Moderna’s mNEXSPIKE COVID-19 Vaccine
Georgia Congresswoman voices strong opposition to vaccine approval
Controversial Reaction to FDA’s Decision
Rep. Marjorie Taylor Greene, R-Ga., has publicly condemned the U.S. Food and Drug Administration’s (FDA) recent decision to authorize Moderna’s mNEXSPIKE COVID-19 vaccine. In a post on X, Greene utilized the acronym “MAHA,” referring to “Make America Healthy Again,” and dismissed the FDA’s move as “Unreal.”
FDA’s Vaccine Approval Criteria
The FDA’s approval applies to mNEXSPIKE for individuals aged 65 and older, as well as those aged 12 to 64 with at least one underlying health condition that increases their risk for severe outcomes from the virus. According to a letter from the FDA to Moderna, this vaccination is intended for those who have previously received any COVID-19 vaccine.
Statistics Highlight Ongoing Public Health Concerns
In a press release, Moderna CEO Stéphane Bancel emphasized the ongoing threat posed by COVID-19, citing that more than 47,000 Americans died from the virus the prior year. Moderna prides itself on being a leader in the field of mRNA medicine.
Greene’s Continued Opposition to COVID-19 Vaccines
Greene has been an active voice against the COVID-19 vaccines, previously calling for the revocation of their FDA approval. In a March tweet, she proclaimed, “COVID-19 vaccines should have never received approval, and they’ve known the entire time how bad the side effects are and deaths caused by them. It’s time to do the right thing. Stop the COVID-19 vaccines.”
Political Implications and Greene’s Position
The congresswoman’s remarks coincide with a broader discontent among a segment of the Republican base, which she openly recognizes. Greene is currently serving her third term in the House of Representatives, where she continues to advocate for policies reflecting her constituents’ apprehensions about COVID-19 vaccinations.
